DE60211681T2 - Verwendung von pyrazolinderivativen bei der herstellung eines medikaments zur prävention und/oder behandlung von proliferativen zellerkrankungen - Google Patents

Verwendung von pyrazolinderivativen bei der herstellung eines medikaments zur prävention und/oder behandlung von proliferativen zellerkrankungen Download PDF

Info

Publication number
DE60211681T2
DE60211681T2 DE60211681T DE60211681T DE60211681T2 DE 60211681 T2 DE60211681 T2 DE 60211681T2 DE 60211681 T DE60211681 T DE 60211681T DE 60211681 T DE60211681 T DE 60211681T DE 60211681 T2 DE60211681 T2 DE 60211681T2
Authority
DE
Germany
Prior art keywords
trifluoromethyl
pyrazole
dihydro
methylsulfonylphenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60211681T
Other languages
German (de)
English (en)
Other versions
DE60211681D1 (de
Inventor
Maria Rosa Cuberes-Altisent
Juana Maria Berrocal-Romero
Maria Montserrat Contijoch-Llobet
Jordi Frigola-Constansa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Application granted granted Critical
Publication of DE60211681D1 publication Critical patent/DE60211681D1/de
Publication of DE60211681T2 publication Critical patent/DE60211681T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60211681T 2001-04-06 2002-03-21 Verwendung von pyrazolinderivativen bei der herstellung eines medikaments zur prävention und/oder behandlung von proliferativen zellerkrankungen Expired - Lifetime DE60211681T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200100818 2001-04-06
ES200100818A ES2174757B1 (es) 2001-04-06 2001-04-06 Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
PCT/ES2002/000137 WO2002080909A1 (es) 2001-04-06 2002-03-21 Empleo de derivados de pirazolinas en la elaboración de un medicamento para la prevención y/o el tratamiento de enfermedades proliferativas celulares

Publications (2)

Publication Number Publication Date
DE60211681D1 DE60211681D1 (de) 2006-06-29
DE60211681T2 true DE60211681T2 (de) 2007-05-16

Family

ID=8497370

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60211681T Expired - Lifetime DE60211681T2 (de) 2001-04-06 2002-03-21 Verwendung von pyrazolinderivativen bei der herstellung eines medikaments zur prävention und/oder behandlung von proliferativen zellerkrankungen

Country Status (26)

Country Link
US (1) US20040034082A1 (https=)
EP (2) EP1516621A3 (https=)
JP (1) JP4451599B2 (https=)
KR (1) KR20040025912A (https=)
CN (2) CN1299682C (https=)
AT (1) ATE326966T1 (https=)
AU (1) AU2002246152B2 (https=)
BR (1) BR0208805A (https=)
CA (1) CA2442974C (https=)
CY (1) CY1105523T1 (https=)
DE (1) DE60211681T2 (https=)
DK (1) DK1384477T3 (https=)
ES (2) ES2174757B1 (https=)
HU (1) HUP0400918A3 (https=)
IL (1) IL158269A0 (https=)
IS (1) IS6973A (https=)
MA (1) MA27019A1 (https=)
MX (1) MXPA03009124A (https=)
NO (1) NO20034470L (https=)
NZ (1) NZ529304A (https=)
PL (1) PL365220A1 (https=)
PT (1) PT1384477E (https=)
RU (1) RU2305545C2 (https=)
UA (1) UA75402C2 (https=)
WO (1) WO2002080909A1 (https=)
ZA (1) ZA200308626B (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077910A1 (en) * 2004-02-16 2005-08-25 Laboratorios Del Dr. Esteve S.A. Pyrazoline derivatives useful for the treatment of cancer
ES2238923B1 (es) * 2004-02-16 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Nuevos derivados pirazolinicos sustituidos.
US7998996B2 (en) 2004-02-17 2011-08-16 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
EP1637522A1 (en) * 2004-09-16 2006-03-22 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
CA2556568A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted pyrazoline compounds for reducing triglycerides in blood
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
WO2007009703A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
EP1746090A1 (en) * 2005-07-15 2007-01-24 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1849776A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Azepane- or Azocane-substituted pyrazoline compounds, their preparation and use as medicaments
ES2327379B1 (es) * 2005-07-15 2010-05-28 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina indolinsustituidos, su preparacion y su uso como medicamentos.
ES2319074B1 (es) * 2005-07-15 2009-12-03 Laboratorios Del Dr. Esteve, S.A. Combinacion de principios activos.
ES2327203B1 (es) * 2005-07-15 2010-06-07 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos relacionados con la coagulacion.
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743642A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
ES2336883B1 (es) * 2005-07-15 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Compuestos de pirazolina sustituidos, con una estereoquimica predeterminada, para la reduccion de trigliceridos en sangre.
ES2326725B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de trastornos alimentarios, que incluyen la obesidad o el sindrome metabolico en pacientes con diabetes desarrollada.
EP1743639A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of coagulation related diseases
EP1749526A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
WO2007009706A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1749527A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazoline compounds for the treatment of the lipid parameters of the metabolic syndrome
EP1743889A1 (en) * 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood
EP1849784A1 (en) * 2006-04-26 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Indoline-substituted pyrazoline compounds, their preparation and use as medicaments
EP1743637A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
ES2316306B1 (es) * 2005-07-15 2009-11-23 Laboratorios Del Dr. Esteve, S.A. Combinacion de un compuesto de pirazolina sustituido y un farmaco utilizado en trastornos relacionados con los alimentos.
ES2326857B1 (es) * 2005-07-15 2010-05-11 Laboratorios Del Dr. Esteve, S.A. Uso de compuestos de pirazolina sustituidos para el tratamiento de los parametros lipidicos del sindrome metabolico.
EP1743636A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. Combination of a substituted pyrazoline compound and a drug used in food-related disorders
WO2007009699A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A Use of substituted pyrazoline compounds and their derivatives for the treatment of cannabinoid system-associated diseases
WO2007009701A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
EP1743643A1 (en) * 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. New formulations of substituted pyrazoline compounds
KR101457637B1 (ko) * 2012-10-24 2014-11-20 건국대학교 산학협력단 디히드로피라졸카르보티오아미드 유도체 및 그 제법 및 그 유도체를 포함하는 항암제 조성물
CN103664785A (zh) * 2013-11-04 2014-03-26 南京大学 一类新颖的二氢吡唑磺胺衍生物的合成及在抗癌药物中的应用
WO2023043778A1 (en) * 2021-09-14 2023-03-23 Maverick Gold (Nv), Llc Methods and systems for titling and trading alternative reserves

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674624T3 (da) * 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
ES2141916T3 (es) * 1993-11-30 2000-04-01 Searle & Co Pirazolil-bencenosulfonamidas sustituidas para el tratamiento de la inflamacion.
US5604253A (en) * 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
ES2137138B1 (es) * 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
US6376519B1 (en) * 1999-06-16 2002-04-23 Temple University-Of The Commonwealth Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2

Also Published As

Publication number Publication date
EP1516621A2 (en) 2005-03-23
CY1105523T1 (el) 2010-07-28
HK1067311A1 (en) 2005-04-08
IL158269A0 (en) 2004-05-12
NZ529304A (en) 2006-02-24
CA2442974A1 (en) 2002-10-17
EP1384477B1 (en) 2006-05-24
EP1516621A3 (en) 2005-05-04
BR0208805A (pt) 2004-07-13
CN1509171A (zh) 2004-06-30
CN1299682C (zh) 2007-02-14
JP4451599B2 (ja) 2010-04-14
AU2002246152B2 (en) 2007-05-31
ES2264723T3 (es) 2007-01-16
ES2174757A1 (es) 2002-11-01
MXPA03009124A (es) 2005-04-11
RU2003132457A (ru) 2005-04-10
HUP0400918A3 (en) 2004-10-28
JP2004525166A (ja) 2004-08-19
EP1384477A1 (en) 2004-01-28
IS6973A (is) 2003-10-03
DE60211681D1 (de) 2006-06-29
US20040034082A1 (en) 2004-02-19
MA27019A1 (fr) 2004-12-20
WO2002080909A1 (es) 2002-10-17
PT1384477E (pt) 2006-09-29
NO20034470D0 (no) 2003-10-06
HUP0400918A2 (hu) 2004-07-28
ATE326966T1 (de) 2006-06-15
CA2442974C (en) 2010-02-23
UA75402C2 (en) 2006-04-17
KR20040025912A (ko) 2004-03-26
NO20034470L (no) 2003-12-05
PL365220A1 (en) 2004-12-27
ZA200308626B (en) 2004-11-05
CN1698602A (zh) 2005-11-23
ES2174757B1 (es) 2003-11-01
RU2305545C2 (ru) 2007-09-10
DK1384477T3 (da) 2006-08-21

Similar Documents

Publication Publication Date Title
DE60211681T2 (de) Verwendung von pyrazolinderivativen bei der herstellung eines medikaments zur prävention und/oder behandlung von proliferativen zellerkrankungen
DE69916828T2 (de) Pyrazoline, ihre herstellung und verwendung als medikamente
DE60220422T2 (de) Substituierte pyrazol-verbindungen zur behandlung von entzündungen
DE69627683T2 (de) Substituierte pyrazolyl-benzolsulfonamide für veterinäre anwendung als entzündungshemmende mittel
DE69833464T2 (de) Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate
DE60103909T2 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
EA022029B1 (ru) Производные тиенопиримидиндиона в качестве модуляторов trpa1
CN112689627A (zh) 三环取代哌啶二酮类化合物
DE602004012559T2 (de) 4-SUBSTITUIERTE DERIVATE VON PYRAZOLOi3,4-D PYRIMIDIN UND DEREN VERWENDUNGEN
CN117088876A (zh) 一种高活性Wnt通路抑制剂化合物
JPH11511761A (ja) チロシンキナーゼ抑制剤としての２環式４−アラルキルアミノピリミジン誘導体
DE69533194T2 (de) PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN
CN101155789B (zh) 1h-喹唑啉-2,4-二酮及其作为ampa-受体配体的用途
ES2861317T3 (es) Moduladores de SOCE, composiciones y usos de los mismos
US20260102387A1 (en) Immunosuppressive compounds
US4713453A (en) Oxabicycloheptane derivatives
DE3782396T2 (de) Pharmazeutische zusammensetzungen, enthaltend ein 2,4-diphenyl-1,3-dioxane derivat und einen inhibitor des thromboxan a2 synthese.
SU1591813A3 (ru) СПОСОБ ПОЛУЧЕНИЯ ЕНОЛОВЫХ ЭФИРОВ АМИДОВ 1, 1-ДИОКСО-6-ХЛОР-4-ОКСИ-2-МЕ'ТИЛ-Ν-(2-ПИРИДИЛ)-2 Н-ТИЕНО[2,3-е]ТИАЗИН-З-КАРБОНОВОЙ КИСЛОТЫ
TW202334157A (zh) 一種Ｗｎｔ通路抑制劑化合物
EP1752149A1 (en) CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression
DE60208554T2 (de) Neue aliphatische verbindung, syntheseverfahren und anwendungsverfahren
DE4444860A1 (de) Verwendung von 1,2-überbrückten 1,4-Dihydropyridinen als Arzneimittel
DE4429786A1 (de) Verwendung von substituierten 6-Amino-4H-pyranen
HK1067311B (en) Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases
HK1085671A (en) Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition